X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used to advance the clinical development of Locate Bio's lead product, LDGraft (rhBMP-2), which is currently undergoing evaluation in early-stage clinical trials for treating patients with degenerative disc disease.
Lead Product(s): rhBMP-2
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: LDGraft
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mercia Ventures
Deal Size: $9.8 million Upfront Cash: Undisclosed
Deal Type: Funding April 29, 2024
Details:
The funding will be used to advance Locate Bio’s proprietary pipeline, including its lead product called LDGraft, a low dose, controlled release rhBMP-2 for the treatment of degenerative disc disease.
Lead Product(s): rhBMP-2
Therapeutic Area: Neurology Product Name: LDGraft
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mercia Asset Management
Deal Size: $13.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
